Neurocrine Biosciences Inc - Company Profile
Powered by 
All the data and insights you need on Neurocrine Biosciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Neurocrine Biosciences Inc Strategy Report
- Understand Neurocrine Biosciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Neurocrine Biosciences Inc (Neurocrine) focuses on the discovery, development, and commercialization of drugs for the treatment of neurological, neuropsychiatric, and neuroendocrine -related disorders. Its lead product, Ingrezza, is a selective VMAT2 inhibitor indicated for the treatment of adults with tardive dyskinesia.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Neurocrine is extensively involved in the development of new drugs by allocating capital and human resources and business development opportunities. Neurocrine has multiple products in the pipeline related to Neurology (Valbenazine, NBI-827104, NBI1076986, and NBI-921352), Endocrinology (Crinecerfont and Efmody) and Neuropsychiatry (Valbenazine, Luvadaxistat, NBI-1065845, NBI-1117568) which are at various phases of development. As of FY2023, the company spent US$565 million for R&D, which stood at 29.9% of the revenue and increased 21.8% YoY. As of December 2023, the company held 22 issued US patents for Ingrezza, a selective VMAT2 inhibitor for the treatment of tardive dyskinesia.
Other Break-up
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer